# Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination–specific humoral and cellular immunity in kidney transplant recipients

**Authors:** Eva Schrezenmeier, Hector Rincon-Arevalo, Annika Jens, Ana-Luisa Stefanski, Charlotte Hammett, Bilgin Osmanodja, Nadine Koch, Bianca Zukunft, Julia Beck, Michael Oellerich, Vanessa Proß, Carolin Stahl, Mira Choi, Friederike Bachmann, Lutz Liefeldt, Petra Glander, Ekkehard Schütz, Kirsten Bornemann-Kolatzki, Covadonga López del Moral, Hubert Schrezenmeier, Carolin Ludwig, Bernd Jahrsdörfer, Kai-Uwe Eckardt, Nils Lachmann, Katja Kotsch, Thomas Dörner, Fabian Halleck, Arne Sattler, Klemens Budde

PMC · DOI: 10.1172/jci.insight.157836 · JCI Insight · 2022-05-09

## TL;DR

Stopping mycophenolate temporarily during a fourth SARS-CoV-2 vaccine dose improves immune responses in kidney transplant recipients.

## Contribution

Demonstrates that antimetabolite hold during booster vaccination enhances humoral and cellular immunity in kidney transplant recipients.

## Key findings

- 76% of patients achieved seroconversion after a fourth vaccine dose during antimetabolite hold.
- B cell and plasmablast responses increased significantly following revaccination.
- Antigen-specific T cell proliferation and activation increased, but cytokine production remained unchanged.

## Abstract

Transplant recipients exhibit an impaired protective immunity after SARS-CoV-2 vaccination, potentially caused by mycophenolate (MPA) immunosuppression. Recent data from patients with autoimmune disorders suggest that temporary MPA hold might greatly improve booster vaccination outcomes. We applied a fourth dose of SARS-CoV-2 vaccine to 29 kidney transplant recipients during a temporary (5 weeks) MPA/azathioprine hold, who had not mounted a humoral immune response to previous vaccinations. Seroconversion until day 32 after vaccination was observed in 76% of patients, associated with acquisition of virus-neutralizing capacity. Interestingly, 21/25 (84%) calcineurin inhibitor–treated patients responded, but only 1/4 belatacept-treated patients responded. In line with humoral responses, counts and relative frequencies of spike receptor binding domain–specific (RBD-specific) B cells were markedly increased on day 7 after vaccination, with an increase in RBD-specific CD27++CD38+ plasmablasts. Whereas overall proportions of spike-reactive CD4+ T cells remained unaltered after the fourth dose, frequencies were positively correlated with specific IgG levels. Importantly, antigen-specific proliferating Ki67+ and in vivo–activated programmed cell death 1–positive T cells significantly increased after revaccination during MPA hold, whereas cytokine production and memory differentiation remained unaffected. In summary, antimetabolite hold augmented all arms of immunity during booster vaccination. These data suggest further studies of antimetabolite hold in kidney transplant recipients.

## Linked entities

- **Proteins:** CD4 (CD4 molecule), CD27 (CD27 molecule), CD38 (CD38 molecule), Mki67 (antigen identified by monoclonal antibody Ki 67)
- **Chemicals:** Mycophenolate (PubChem CID 6918995), azathioprine (PubChem CID 2265)
- **Diseases:** SARS-CoV-2 (MONDO:0100096)

## Full-text entities

- **Genes:** SELL (selectin L) [NCBI Gene 6402] {aka CD62L, LAM1, LECAM1, LEU8, LNHR, LSEL}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, UCHL1 (ubiquitin C-terminal hydrolase L1) [NCBI Gene 7345] {aka HEL-117, HEL-S-53, NDGOA, PARK5, PGP 9.5, PGP9.5}, TNFRSF9 (TNF receptor superfamily member 9) [NCBI Gene 3604] {aka 4-1BB, CD137, CDw137, ILA, IMD109}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, CD24 (CD24 molecule) [NCBI Gene 100133941] {aka CD24A}, CD40LG (CD40 ligand) [NCBI Gene 959] {aka CD154, CD40L, HIGM1, IGM, IMD3, T-BAM}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, CD38 (CD38 molecule) [NCBI Gene 952] {aka ADPRC 1, ADPRC1, cADPR1}, S (surface glycoprotein) [NCBI Gene 43740568] {aka spike glycoprotein}, CD14 (CD14 molecule) [NCBI Gene 929], STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CD79A (CD79a molecule) [NCBI Gene 973] {aka IGA, IGAlpha, MB-1, MB1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CABIN1 (calcineurin binding protein 1) [NCBI Gene 23523] {aka CAIN, KB-318B8.7, PPP3IN}, CD27 (CD27 molecule) [NCBI Gene 939] {aka S152, S152. LPFS2, T14, TNFRSF7, Tp55}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}
- **Diseases:** COVID-19 (MESH:D000086382), autoimmune disorders (MESH:D001327), allograft injury (MESH:D000092122), toxicity (MESH:D064420), deterioration of kidney function (MESH:D058186), rheumatic and musculoskeletal diseases (MESH:D009140), HS (MESH:C567159), impaired kidney function (MESH:D007674), CL (MESH:D002971), infection (MESH:D007239), Chronic Kidney Disease (MESH:D051436)
- **Chemicals:** prednisone (MESH:D011241), steroids (MESH:D013256), tacrolimus (MESH:D016559), creatinine (MESH:D003404), Aza (MESH:D001379), Alexa Fluor 488 (MESH:C000711379), BAU (-), XMP (MESH:C011141), dd- (MESH:C007792), Alexa Fluor 647 (MESH:C569686), MPA (MESH:D009173),  (MESH:D000963),  (MESH:D007166)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Homo sapiens (human, species) [taxon 9606], Betapolyomavirus hominis (species) [taxon 1891762]
- **Cell lines:** SJ25C1 — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_A8SF), EH12.1 — Homo sapiens (Human), Hairy cell leukemia, Cancer cell line (CVCL_L804), DREG-56 — Mus musculus (Mouse), Hybridoma (CVCL_G133), ML5 — Homo sapiens (Human), Ovarian serous cystadenoma, Transformed cell line (CVCL_D278)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC9090237/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC9090237/full.md

## References

46 references — full list in the complete paper: https://tomesphere.com/paper/PMC9090237/full.md

---
Source: https://tomesphere.com/paper/PMC9090237